Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.

Timeline

Start

2025-01-08

Primary completion

2027-06-30

Completion

2027-12-31

Drugs

Indications